What is it about?
Risk stratification is recommended to predict outcome and guide treatment strategies. We show that both the pediatric pulmonary arterial hypertension (PAH) risk stratification tool proposed at the World Symposium on Pulmonary Hypertension in 2013 and a simplified pediatric risk model indeed predicted outcome in children with idiopathic and hereditary PAH.
Featured Image
Read the Original
This page is a summary of: The Clinical Value of Proposed Risk Stratification Tools in Pediatric Pulmonary Arterial Hypertension, American Review of Respiratory Disease, November 2019, American Thoracic Society,
DOI: 10.1164/rccm.201902-0266le.
You can read the full text:
Contributors
The following have contributed to this page
